Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?
The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse. 150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups. Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy . Group 2 - of 75 persons will...
Brief Summary
The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse.
150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups.
Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy .
Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will take abdominal radiograph to evaluate the presence of steinstrasse.
- Study Type: Observational
- Study Design: Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal, Time Perspective: Prospective
Intervention(s) in this Clinical Trial
- Drug: tamsulosin 0.4mg
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- size of stone 1-2 cm
Exclusion Criteria:
- ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 15 Years
Maximum Age for this Clinical Trial: 85 Years
Clinical Trial Investigator Information
Lead Investigator: HaEmek Medical Center, Israel Other
Overall Clinical Trial Officials and Contacts
doron perez Principal Investigator Urology department: Haemek Medical Center
Overall Contact: DORON PEREZ, M.D. +972-4-6495115 perez_do@clalit.org.il
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00489723
Study ID Number: 0056-07-EMC
ClinicalTrials.gov Identifier: NCT00489723
Health Authority: Israel: Ethics Commission
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00489723
